Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
25 October 2019

ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter, 2019

21 October 2019

ORYZON updates on new activities

3 October 2019

ORYZON Presents New Positive REIMAGINE Efficacy Data of Vafidemstat in the Treatment of Aggression

30 September 2019

ORYZON presents positive efficacy results on iadademstat in ED-SCLC patients at ESMO-2019

23 September 2019

ORYZON updates on new activities

10 September 2019

ORYZON presents new positive efficacy data on vafidemstat for treatment of aggression

9 September 2019

ORYZON’s iadademstat shows efficacy signs in relapsed SCLC

3 September 2019

ORYZON to present at upcoming international conferences

9 August 2019

Oryzon to present at upcoming international conferences

30 July 2019

ORYZON Reports Financial Results and Corporate Update for the First Half Ended June 30, 2019

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 30
  • Page 31
  • Page 32
  • Page 33
  • Current page 34
  • Page 35
  • Page 36
  • Page 37
  • Page 38
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel